Thanks, I do understand the point, I think, and the sense of exasperation too. But what's self-evident in the abstract is less so in the real world of trade-offs, limited resources, opportunity costs and so on. If the goal is to reduce the likelihood of dangerous mutations, and the means is to reduce the number of instances of the virus, we still have to ask, Which instances? Where? Should our limited stock of vaccines go on children, or on bringing forward second doses for adults, or on helping poorer nations? If that's self-evident to you, good on you: I've no real clue, just some intuitions.
The letter I'm referring to, by the way, raised a point I've not seen made elsewhere, which is that "instances of the virus" can be thought of not just in terms of cases but on the cellular level, in terms of how many times the virus replicates inside individuals. On the whole it tends to replicate much, much less in children than in adults (another way of saying that children get less sick). Is this pertinent to the decision as to where to "spend" the vaccines? Again I've no idea but it seems a question worth asking.
It's important to think in terms of limited resources and opportunity costs not just in relation to vaccines but attention. ISage, The Citizens and their acolytes are going to spend the next couple of weeks trying to pressurise the JCVI and government on their vaccine decision by hosing us down with scary-looking data about long covid in children, hospitalisation of children etc. Is this the best use of their time/our attention/government attention? As with masks and the timing of Freedom Day, I''m going to suggest "No", and not only because the real risk of mutation might well lie elsewhere than 12-17 year olds in the UK.